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Randomised controlled trials are the ideal way to assess the effects of interventions. Small trials 
are useful for generating pilot data to determine samples sizes for larger trials, but can produce 
unreliable or biased results if they are considered in their own right. We investigate the impact of 
small sample sizes due either to inadequate recruitment targets or high attrition rates on the 
results of fatty acid intervention trials. Data from our large trial of DHA supplementation during 
pregnancy with minimal attrition are used for illustration. Our findings demonstrate that 
recruiting fewer participants or neglecting to follow up difficult participants can lead to 
substantially different results and alter conclusions about the effectiveness of the intervention. 
Developing strategies for overcoming these inadequacies should be a top priority in fatty acid 
intervention trials. 
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Randomised controlled trials (RCTs) are generally considered to be the gold standard for judging 
the effectiveness of an intervention [1]. However, it can be difficult to draw meaningful 
conclusions from RCTs when the number of participants in the trial (the sample size) is 
inadequate. Statisticians would describe such a trial as underpowered to detect clinically 
important treatment effects, if they are present. Underpowered trials are problematic as, despite 
the enthusiasm of many investigators, they are more likely to produce significant findings that 
are the result of chance, rather than a real effect of the intervention [2, 3]. Underpowered trials 
have also been deemed unethical, as they expose participants to interventions with little chance 
of providing a clear answer regarding their effectiveness [4]. Trials that become underpowered 
due to high attrition rates (participant losses due to various causes) are even more problematic, 
since they can produce biased estimates of the treatment effect. Such bias is likely to occur when 
the participants who withdraw or are lost to follow up have different characteristics or outcomes 
than those participants who provide complete data, or when the attrition rate differs between 
treatment groups [5-7]. Attrition can also reduce the generalisability of the trial results [5]. It is 
therefore crucial to ensure that RCTs have adequate sample sizes with sufficient power to detect 
clinically important treatment effects, by choosing appropriate recruitment targets and 
minimising attrition rates. 
 
Conducting adequately sized trials in fatty acid research can be especially challenging. Since 
background levels of the fatty acid of interest are present in the control group due endogenous 
synthesis and background diet intake, the difference between treatment groups in the fatty acid of 
interest can be reduced [8]. As a result, the difference in outcomes that is achievable with a fatty 
acid intervention can be smaller than for other types of interventions, and hence a larger sample 
size may be needed. Despite this, many RCTs of fatty acid interventions suffer from small 
sample sizes due to inadequate recruitment targets and/or high attrition rates, as highlighted by 
systematic reviews of fatty acid interventions [e.g. 9, 10]. A reminder of the importance of 




The aim of this article is to demonstrate how trials involving small numbers of participants can 
lead to questionable results, using data from our large-scale Docosahexaenoic acid (DHA) to 
Optimize Mother Infant Outcome (DOMInO) trial with minimal attrition for illustration [11]. 
 
2. Patients and Methods 
 
2.1 The DOMInO Trial 
 
The DOMInO trial was a double-blind, multicenter RCT conducted in five maternity hospitals in 
Australia between 2005 and 2009 (Australian and New Zealand Clinical Trials Registry 
Identifier ACTRN12605000569606; anzctr.org.au) and has been described in detail previously 
[11]. Briefly, women with a singleton pregnancy between 18 and 21 weeks’ gestation who were 
not already taking a prenatal supplement containing DHA were eligible to participate. Women 
providing written informed consent were randomised to the DHA or control group and were 
asked to consume three DHA-rich fish oil capsules or vegetable oil capsules per day, 
respectively, from trial entry until delivery. All procedures were conducted in accordance with 
the approval of the relevant Human Research Ethics Committees at each maternity hospital.  
 
The aim of the DOMInO trial was to determine the effect of DHA supplementation during 
pregnancy on postnatal depression in the women, and cognitive and language development in the 
infants. Postnatal depression was assessed at six weeks and six months postpartum using the 
Edinburgh Postnatal Depression Scale (EPDS) [12] and a score of 12 or more was used to 
indicate probable depression. Cognitive and language development were assessed at 18 months 
of age (corrected for premature birth) using the Bayley Scales of Infant and Toddler 
Development, Third Edition (Bayley-III) [13]. The Bayley-III produces standardised scores with 
a mean of 100 and a standard deviation of 15, where lower scores represent poorer performance. 
 
High recruitment targets were set for the DOMInO trial [11]. Sample size calculations indicated 
that 2280 women (1140 per group) should be recruited to detect a clinically important 4.2% 
absolute reduction in the prevalence of postnatal depression from 16.9% in the control group 
with 80% power. A 4.2% reduction was chosen on the basis of epidemiological data that 
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suggested a 7-8% reduction [14] and the possibility that part of this effect may be due to residual 
confounding, while the control group prevalence of 16.9% was estimated from Australian 
population data [15]. Only 630 infants (315 per group) were required to detect a clinically 
meaningful 5 point improvement in the mean cognitive and language scores separately for boys 
and girls, based on 80% power and the known standard deviation of the Bayley-III standardised 
scores of 15 [13]. A 5 point improvement was of interest as previous studies showing differences 
of 4-5 points had prompted changes in health policy [16, 17]. Developmental assessment was 
therefore planned for only a subset of infants to minimise both the cost of the trial and the burden 
on participants. A number of strategies for minimising attrition were implemented, including 
collecting up to four alternative contacts for participants at trial entry, and keeping in contact via 
mailing a regular newsletter that included a change of address slip.  
 
2.2 Statistical Methods 
 
A post-hoc exploratory analysis of data from the DOMInO trial was performed to determine how 
the results might have changed if the sample size had been smaller due to recruiting fewer 
participants or neglecting to follow up difficult participants. Language scores at 18 months of 
age and postnatal depression at six months postpartum were used for illustration.  
 
To investigate the potential impact of small sample sizes due to inadequate recruitment targets, 
we estimated the effect of DHA supplementation on language scores in three different groups of 
DOMInO participants: (i) all infants who completed the developmental assessment; (ii) 100 
different random samples of 50 infants (25 per group) selected from the infants who completed 
the developmental assessment; and (iii) after every 50 infants had completed the developmental 
assessment. In each case, the mean language score was compared between the DHA and control 
groups using a two-sample t-test. The percentage of random samples of 50 infants where the 
estimated treatment effect was expected to exceed the clinically important difference of 5 points, 
just by chance, was calculated based on properties of the normal distribution. 
 
To investigate the potential impact of small sample sizes due to high attrition rates, we estimated 
the effect of DHA supplementation on postnatal depression at six months postpartum in two 
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different subsets of DOMInO participants: (i) all women who completed the EPDS; and (ii) after 
excluding women who were difficult to follow up, defined as completing the EPDS more than 30 
days after it was due, or requiring telephone follow up based on incomplete responses to the 
questionnaire. For each of these subsets, the proportion of women who had probable depression 




Recruitment targets were exceeded for the DOMInO trial to ensure adequate sample sizes would 
remain after any attrition. A total of 2399 women (1197 DHA, 1202 control) were enrolled in the 
trial and 726 infants (351 DHA, 375 control) were selected for the developmental assessment 
Attrition rates for the trial were kept to a minimum. EPDS scores at six months postpartum were 
obtained from 2341 (97.6%) women, while 692 (95.3%) infants completed the language 
assessment at 18 months of age. The primary findings of the trial have been reported in detail 
elsewhere [11]. 
 
3.1 Impact of Inadequate Recruitment Targets 
 
Based on all 692 infants who completed the language assessment, the mean (SD) language score 
from the Bayley-III was 96.5 (13.6) for the DHA group and 98.2 (15.3) for the control group. 
The difference in means (DHA minus control) was -1.7 points (95% confidence interval, -3.9 to 
0.5), indicating that there was insufficient evidence to support the hypothesis that the mean 
language score differed between the treatment groups (P=0.13). Similar results have been 
reported for this outcome elsewhere using more complex statistical methods [11]. A high degree 
of confidence can be placed in these results, due to the large sample size and minimal attrition 
rate. 
 
In order to demonstrate the effect of inadequate recruitment targets on these results, we estimated 
the effect of DHA supplementation on language for 100 random samples of 50 infants (25 per 
group). Treatment effect estimates ranged from a reduction in the mean score of 8.4 points, to an 
increase in the mean score of 7.8 points, depending on the random sample chosen (Figure 1). 
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There was one random sample where DHA supplementation had a significant positive effect and 
three random samples where it had a significant negative effect on the mean language score. 
These small samples therefore could have led to conclusions that differed from the main trial 
findings when all infants were included in the analysis. None of the other random samples 
showed a statistically significant effect of DHA supplementation on language. For 20% of 
random samples, the estimated treatment effect exceeded the clinically important difference in 
mean language scores of 5 points. If DHA supplementation had no effect on language, a 
difference of 5 points or more would be expected just by chance in 24% of random samples. 
These findings are therefore consistent with the lack of effect of DHA supplementation on 
language seen among all infants. 
 
Another way to demonstrate the effect of inadequate recruitment targets on the trial results is to 
examine the cumulative effect of DHA supplementation on language after every 50 infants 
completed the developmental assessment. Treatment effect estimates varied greatly in the early 
stages of the DOMInO trial, ranging from an increase in the mean score of 3.1 points when only 
50 infants had been assessed, to a reduction of 3.6 points when 300 infants had been assessed 
(Figure 2). The treatment group differences achieved statistical significance in favour of the 
control group when the sample size was 300, 350, 450 or 500 infants and the smallest p-value 
observed was 0.02. As the trial progressed and the sample size increased to the target required to 
ensure adequate power, the estimated effect of DHA supplementation stabilised and the mean 
language scores did not differ significantly between the treatment groups.  
 
3.2 Impact of High Attrition Rates 
 
Based on all 2341 women who completed the EPDS at six months postpartum, 9.6% of women 
in the DHA group and 11.2% of women in the control group had scores indicating probable 
depression. Despite the large sample size and minimal attrition rate, there was no evidence to 
suggest that DHA supplementation reduced the prevalence of postnatal depression (P=0.21). 
Similar findings have previously been reported for this outcome using more complex statistical 




As with all trials, some DOMInO participants were easier to follow up than others. There were 
784 (33.5%) women who were difficult to follow up for assessing postnatal depression at six 
months postpartum. These women had different characteristics compared with women who were 
easy to follow up; they were more likely to be younger, less educated, smokers, have a history of 
depression and belong to the DHA group (Table 1). Such differences in observed (or 
unobserved) characteristics can introduce bias into estimated treatment effects when these 
women are excluded from the analysis. In the subset of 1557 (66.5%) women who were easy to 
follow up, DHA supplementation was found to reduce postnatal depression, with a prevalence of 
8.2% observed in the DHA group and 11.1% in the control group (P=0.05). This result contrasts 
with the null finding when all women were included in the analysis and should be considered 
unreliable due to the potential biases. 
 
4. Discussion and Conclusions 
 
This report highlights the importance of achieving adequate sample sizes in fatty acid 
intervention trials. The large recruitment targets and high follow up rates attained in our 
DOMInO trial of DHA supplementation in pregnancy provided an opportunity to illustrate what 
can go wrong when trials are too small. While problems with inadequate sample sizes have been 
discussed in general previously [e.g. 2, 3-7], small trials continue to be conducted in fatty acid 
research and a review of the issues in this context is timely. The results of our exploratory 
analyses demonstrate that less confidence can be placed in the results of a small trial, since 
recruiting more participants or improving follow up rates could lead to substantially different 
results. Small trials can still be valuable for contributing to meta-analyses or providing pilot data 
to help plan future trials with adequate power, but are unlikely in themselves to provide a clear 
answer regarding the effectiveness of the intervention.  
 
We found that DHA supplementation could have a significant positive effect, a significant 
negative effect, or no significant effect on language development in different random samples of 
infants who completed the language assessment in the DOMInO trial. If DHA supplementation 
really has no impact on language, significant positive and negative effects can be expected in 
some samples of infants, just by chance. Although this is true in samples of any size, the likely 
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magnitude of chance treatment effects decreases as the sample size increases. This means that 
any false positive findings are expected to be smaller in larger samples, and are therefore less 
likely to be considered clinically important. As an example, for a trial with a total sample size of 
only 50 infants, we found there is a 24% chance of observing a clinically meaningful difference 
in mean language scores between the treatment groups if DHA supplementation actually has no 
effect on language. This can be reduced to less than a 1% chance if the total sample size for the 
trial is increased to 250 infants. These calculations emphasize the importance of replicating 
findings reported from trials with few participants in adequately powered trials before 
considering changing public health policy or clinical practice guidelines.  
 
The target sample size for a trial should depend on a number of factors, including the minimum 
clinically important difference to be detected between the treatment groups and the desired 
power [4, 18, 19]. In fatty acid intervention trials, the presence of the fatty acid of interest in the 
control group due to endogenous synthesis and dietary intake should also be considered, as this 
can reduce the difference between treatment groups in the fatty acid of interest and hence the 
achievable difference in the primary outcome, which increases the sample size required [18]. 
Non-compliance is another important factor to consider in sample size calculations for fatty acid 
intervention trials. While participants in the intervention group can fail to take the intervention in 
any trial, the risk of participants in the control group taking the intervention is particularly high 
in fatty acid research when readily available foods and dietary supplements contain the fatty acid 
of interest. Compliance with the assigned treatment should be encouraged throughout the trial 
and the sample size can be increased to account for non-compliance [18]. By choosing a target 
sample size that provides high power to detect a clinically meaningful treatment effect, should 
one exist, and low risk of finding such an effect just by chance, researchers are more likely to be 
able to draw meaningful conclusions from their trials. 
 
Our analysis of the postnatal depression data from the DOMInO trial illustrates the problems 
with high attrition rates in fatty acid intervention trials. We found that women who were difficult 
to follow up had different characteristics than those who were not difficult to follow up, and that 
excluding the difficult to follow up women from the analysis resulted in different conclusions 
about the effectiveness of the intervention. This emphasizes the need to achieve high follow up 
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rates. In fatty acid intervention trials, the maximum follow up rate that can realistically be 
attained depends on the population being studied, the nature and intensity of the intervention, and 
the length of follow up planned. While attrition rates of up to 5% have traditionally been 
considered acceptable [20], greater emphasis is now being placed on the potential implications of 
any losses to follow up, rather than defining acceptable attrition rates [5]. Attrition is likely to 
introduce bias because the participants who withdraw or are lost to follow up inevitably have 
different characteristics or outcomes than those participants who provide complete data [5-7]. 
Complex statistical methods are available for dealing with missing data due to attrition [21], but 
these rely on untestable assumptions about the missing values and should not become a substitute 
for time and effort spent following up trial participants. Strategies for minimising attrition are 
therefore crucial, and these have been discussed elsewhere [7, 22]. By achieving high follow up 
rates, researchers are more likely to draw appropriate conclusions from their trials. 
 
In summary, our findings highlight the importance of ensuring RCTs have adequate sample sizes 
by recruiting sufficient participants and minimising attrition rates. Achieving an adequate sample 
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Table 1. Characteristics of women by whether they were easy or difficult to follow up for 





Age at trial entry (years)* 29.8 (5.3) 27.3 (6.0) 
Completed secondary education 1066 (68.5) 414 (52.8) 
Completed further education 1098 (70.5) 498 (63.5) 
Smoked at trial entry or leading up to pregnancy 420 (27.0) 329 (42.0) 
Previous or current medical diagnosis of depression 346 (22.2) 220 (28.1) 
Assigned to DHA supplementation group 758 (48.7) 420 (53.6) 
Values are number (percent) unless otherwise indicated. 





Figure 1. Difference in mean language score (DHA minus control) for 100 different random 








Figure 2. Difference in mean language score (DHA minus control) after every 50 infants 
completed the developmental assessment. Stars indicate statistically significant differences 
(P<0.05). Dots indicate non-significant differences. 
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